Pages that link to "Q44086963"

The following pages link to Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). (Q44086963):

Displaying 41 items.

• PI3K/AKT/mTOR Pathway in Angiogenesis (Q21129332) (← links)
• Expanding the therapeutic repertoire of epidermal growth factor receptor blockade: radiosensitization (Q24803435) (← links)
• Silencing the epidermal growth factor receptor gene with RNAi may be developed as a potential therapy for non small cell lung cancer (Q24814041) (← links)
• Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy (Q28475894) (← links)
• Computational modelling of anti-angiogenic therapies based on multiparametric molecular imaging data (Q30564565) (← links)
• Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK (Q33562476) (← links)
• An imaging-based tumour growth and treatment response model: investigating the effect of tumour oxygenation on radiation therapy response (Q33641209) (← links)
• Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies (Q33644407) (← links)
• Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancer (Q33843578) (← links)
• EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases (Q34461771) (← links)
• Quality-of-life benefits and evidence of antitumour activity for patients with brain metastases treated with gefitinib (Q35602197) (← links)
• Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors (Q35647847) (← links)
• The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines (Q35649008) (← links)
• Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer (Q35951086) (← links)
• Cellular responses to EGFR inhibitors and their relevance to cancer therapy (Q36003118) (← links)
• Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity (Q36065216) (← links)
• Molecular targets for tumor radiosensitization (Q36126009) (← links)
• Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells (Q36673777) (← links)
• Combined action of EGFR tyrosine kinase inhibitors and whole-brain radiotherapy on EGFR-mutated non-small-cell lung cancer patients with brain metastasis (Q36684011) (← links)
• Additive interaction of gefitinib ('Iressa', ZD1839) and ionising radiation in human tumour cells in vitro (Q36696568) (← links)
• Epidermal Growth Factor Receptor–Targeted Radioimmunotherapy of Human Head and Neck Cancer Xenografts Using 90Y-Labeled Fully Human Antibody Panitumumab (Q36777329) (← links)
• EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality (Q37174372) (← links)
• Modulating the tumor microenvironment to increase radiation responsiveness (Q37613364) (← links)
• PD 0332991, a selective cyclin D kinase 4/6 inhibitor, sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors. (Q37709050) (← links)
• Reversion of the ErbB malignant phenotype and the DNA damage response. (Q38047648) (← links)
• Linking the history of radiation biology to the hallmarks of cancer. (Q38210491) (← links)
• Molecular biology and immunology of head and neck cancer (Q38483321) (← links)
• A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839) (Q38603140) (← links)
• Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/- cetuximab in oesophageal cancer. (Q38757690) (← links)
• Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. (Q39887931) (← links)
• Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer (Q39939644) (← links)
• Gefitinib ('IRESSA', ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation. (Q40534312) (← links)
• Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines (Q41778604) (← links)
• Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF. (Q44561177) (← links)
• Bevacizumab and gefitinib enhanced whole-brain radiation therapy for brain metastases due to non-small-cell lung cancer (Q47142558) (← links)
• The inhibition of epidermal growth factor receptor signaling by hexagonal selenium nanoparticles modified by SiRNA. (Q50488952) (← links)
• [Clinical developments for the EGFR-TKI combined with radiotherapy in advanced non-small cell lung cancer]. (Q53238870) (← links)
• Upfront whole brain radiotherapy for multiple brain metastases in patients with EGFR-mutant lung adenocarcinoma (Q64096454) (← links)
• [Designer-drugs in tumor treatment] (Q80098830) (← links)
• Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer (Q90300758) (← links)
• Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant (Q92354826) (← links)